Navigation Links
Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundation's 2011 M. Judah Folkman International Conference in Cambridge, Mass.
Date:9/23/2011

CAMBRIDGE, Mass., Sept. 23, 2011 /PRNewswire/ -- Efficacy and safety data from VELOUR, the pivotal Phase III trial of aflibercept (VEGF Trap, ZALTRAP™) for the treatment of metastatic colorectal cancer (mCRC) will be presented by Edith P. Mitchell, M.D., a leading cancer researcher, at the Angiogenesis Foundation's 9th Annual M. Judah Folkman International Conference: Antiangiogenesis: New Frontiers in Therapeutic Development on October 29-30, 2011 at the Hyatt Regency Cambridge.

The VELOUR presentation will be the first time the results are presented in the U.S.

Registration for the conference is now open. To review the topic and speaker agenda visit http://www.angio.org/programs-cp-aa11.php.

Dr. Mitchell will join a roster of distinguished speakers at the conference, including Dr. Robert S. Kerbel of the University of Toronto, and Dr. Adriana Albini of IRCCS Multimedica, Italy.

This year's conference will include presentations by leaders from Harvard Medical School, the U.S. National Cancer Institute, University of Texas MD Anderson, Memorial Sloan Kettering Cancer Center, Stanford University, Queen's University Belfast, Johannes Gutenberg University Mainz, IRCCS Multimedica Milan, and other top research institutions.

Topics to be covered at this year's meeting include:

  • Anti-VEGF therapy resistance and antiangiogenic escape
  • VEGF-independent tumor angiogenesis
  • Glioblastoma vasculature and stem cells
  • Novel therapy biomarkers
  • Early intervention and prevention through antiangiogenesis

As the world's leading non-profit organization dedicated to advancing the field of angiogenesis research, the Angiogenesis Foundation takes a multidisciplinary approach to its annual conference, bringing together experts and key stakeholders from basic research, life sciences industry, clinical investigation, and government to foster new collaborations and exchanges between faculty and attendees.

Due to limited space, early registration is encouraged. For additional information please contact, Michelle Sylvanowicz at (617) 401-2779.


'/>"/>
SOURCE The Angiogenesis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Februar 2017 ITL Limited, ( ASX: ... ist erfreut, für das zum 31. Dezember 2016 ... exzellente Ergebnisse vorlegen zu können. Eine vollständige Präsentation ... finden Sie hier . ... 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s ... of his paramedic experiences. Schanssema describes the tragedies he saw, as well as his ... them. , Schanssema, initially unsure of the career path he wanted to take, found ...
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will ... the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our ... This year’s Bunkum winner is the Center for American Progress (CAP), for its report, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Los Angeles-based weight ... of WE TV’s “Mama June: From Not to Hot,” which will begin airing on ... June Shannon, known to millions from the 2012 reality television series, “Here Comes Honey ...
Breaking Medicine News(10 mins):